|Where is Aimmune Therapeutics located?|
|Our corporate offices are located at 8000 Marina Boulevard, Suite 200, Brisbane, California 94005-1884|
|When was Aimmune founded?|
|The company was founded on June 24, 2011 as Allergen Research Corporation (ARC), a Delaware corporation. In May 2015, we changed our name to Aimmune Therapeutics, Inc.|
|What is Aimmune’s CUSIP number?|
|Our CUSIP number is 00900T 107.|
|On what stock exchange and under what symbol are Aimmune’s shares traded? When did the company go public?|
|Aimmune is listed on the Nasdaq Global Select Market under the ticker symbol AIMT. Our initial public offering (IPO) was on August 5, 2015.|
|How can someone buy or sell shares of Aimmune’s stock?|
|Investors may purchase Aimmune’s stock through a licensed securities broker. We do not offer a direct purchase plan for investors.|
|Who is Aimmune’s transfer agent?|
Aimmune’s transfer agent is Wells Fargo Shareowner Services.
|Who do I contact regarding lost stock certificates, address changes, and changes of ownership or name in which shares are held?|
Please contact our transfer agent, Wells Fargo Shareowner Services.
|Does Aimmune issue dividends on its common stock?|
|Aimmune does not pay cash dividends on its common stock.|
|Who are Aimmune’s independent auditors?|
Our independent auditors are KPMG LLP.
|Who is Aimmune’s outside legal counsel?|
Our outside legal counsel is Latham & Watkins LLP.
|When is Aimmune’s fiscal year-end?|
|Our fiscal year-end is December 31.|
|How can I contact Aimmune for any additional questions?|
|Please submit an inquiry via our contact form.|